Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Kiba, Takayoshi; Ito, Takuo; Nakashima, Toshihisa; Okikawa, Yoshiko; Kido, Miki; Kimura, Akiko; Kameda, Keita; Miyamae, Fumiaki; Tanaka, Suzuko; Atsumi, Misao; Sumitani, Yoko; Shitakubo, Yoshimi; Niimi, Hiromasa

doi:10.1186/1471-2407-14-462

Cited by 36 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated LDH has been found to be an adverse prognostic indicator for survival in patients with MM [26,27]. Our study proves that if the level of LDH of MM patients is ≥240U/L, poor survival is a highly possible result.…”

Section: Discussionsupporting

confidence: 61%

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…An inverse relationship between LDH levels and length of survival has also been identified in many tumor types, including melanoma 15, breast cancer 16, myeloma 17, hepatocellular carcinoma 18, seminoma 19, nasopharyngeal cancer 20, lung cancer 21, colorectal cancer 10, renal cancer 22, oral cancer 23, and pancreatic cancer 24. For gynecologic malignancies, a strong association between the elevated expression of LDH and an aggressive phenotype has been noted in patients with ovarian and uterine carcinoma 25, 26.…”

Section: Discussionmentioning

confidence: 95%

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

For locally advanced cervical cancer (LACC), hypoxia is a characteristic property. This study aimed to investigate whether baseline lactic dehydrogenase (LDH) level, which is a marker of hypoxia, had clinical value in determining neoadjuvant chemotherapy (NACT) response and prognosis for LACC patients. The study cohort included 418 patients with a median follow‐up of 37.5 months. Cox proportional hazards models were used to assess the prognostic value of baseline LDH levels. Multivariate logistic regression analysis was performed to identify independent predictors of complete response after NACT. Backward stepwise selection with the Akaike information criterion was used to identify factors that could be entered into the multivariate regression model. Compared with patients with LDH levels <252.0 μ/L, patients with LDH levels ≥252.0 μ/L were more likely to have an elevated level of squamous cell carcinoma antigen, lymphatic vascular space involvement, lymph node metastasis, and positive parametrium and achieved lower complete remission rates. Baseline LDH levels ≥252.0 μ/L was an independent prognosticator for recurrence‐free survival (adjusted hazard ratio [HR], 3.56; 95% confidence interval [CI] 2.22–5.69; P < 0.0001) and cancer‐specific survival (adjusted HR, 3.08; 95% CI, 1.89–5.01; P < 0.0001). The predictive value of baseline LDH value remained significant in the subgroup analysis. LDH level ≥252.0 μ/L was identified as an independent predictor of complete remission after NACT (adjusted odds ratio [OR], 0.29; 95% CI, 0.15–0.58; P < 0.0001). Baseline LDH ≥252.0 μ/L is an independent prognostic predictor for patients receiving neoadjuvant chemotherapy for LACC. It helps distinguish patients with different prognosis and select patients who are more likely to benefit from NACT.

show abstract

“…Elevated LDH has been found to be an adverse prognostic indicator for survival in patients with MM [67,68]. Extramedullary disease is generally associated with poor outcomes [65], while extramedullary relapses are associated with lower overall survival and increased risk of bone plasmacytomas or fractures [64].…”

Section: High-risk Diseasementioning

confidence: 99%

Clinical characteristics of patients with relapsed multiple myeloma

Dimopoulos

Terpos

Niesvizky

et al. 2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics.

show abstract

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Cited by 36 publications

References 31 publications

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer

Clinical characteristics of patients with relapsed multiple myeloma

Contact Info

Product

Resources

About